Companies /Healthcare

Veeva Systems Inc - Class A

NYSE: VEEV Health Information Services
$286.48
â–² $41.57 (+16.97%) today
Markets open · 12:48pm ET

Q2 2027 Earnings

Reported Aug 26, 2026, 4:06pm ET · SEC source
$2.35
Beat +5.77%
EPS · est. $2.22 Adjusted
$928.0M
Beat +2.51%
Revenue · est. $905.3M
7 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+6%+12%Aug 26Aug 27report 4:06pm ETearnings+0.6%+12.5%
0+6%+12%Aug 26Aug 27earnings+0.6%+12.5%
VEEV +12.5%S&P 500 +0.6%
0+6%+12%Aug 26Aug 27report 4:06pm ETearnings+1.0%+12.5%
0+6%+12%Aug 26Aug 27earnings+1.0%+12.5%
VEEV +12.5%NASDAQ +1.0%
−6%0+6%+12%Aug 25Aug 27report 4:06pm ETearnings+0.5%+7.9%
−6%0+6%+12%Aug 25Aug 27earnings+0.5%+7.9%
VEEV +7.9%S&P 500 +0.5%
−6%0+6%+12%Aug 25Aug 27report 4:06pm ETearnings+0.8%+7.9%
−6%0+6%+12%Aug 25Aug 27earnings+0.8%+7.9%
VEEV +7.9%NASDAQ +0.8%
+16.37%
Day of report

Did VEEV Beat Earnings? Q2 2027 Results

Veeva Systems delivered a strong fiscal second quarter, with momentum across its cloud platform driving results well ahead of Wall Street expectations and extending the company's streak of beating consensus EPS estimates to six consecutive quarters. The life sciences software specialist posted adjusted EPS of $2.35, clearing the $2.22 consensus by 5.77%, while revenue climbed 17.6% year over year to $927.96 million, beating estimates of $905.26 million by 2.51%. The standout driver was Vault CRM, which had its strongest quarter to date, with more than 180 customers live and 12 top 20 biopharma commitments globally, underscoring durable demand for Veeva's commercial cloud suite. GAAP net income rose 37% to $273.43 million, aided in part by the absence of $30.63 million in litigation settlement charges that weighed on the year-ago period. Looking ahead, management raised its full-year fiscal 2027 revenue guidance to $3.68 to $3.69 billion, with non-GAAP diluted EPS of approximately $9.21, reflecting continued confidence in its expanding AI and agentic workflow offerings.

Key Takeaways
  • Vault CRM had its best quarter with over 180 customers live, including five top 20 biopharmas
  • Subscription revenue growth of 16% year over year driven by both Commercial and R&D solutions
  • Professional services and other revenue grew 24% year over year
  • Non-GAAP operating margin held at 44.8%
  • AI adoption accelerating across product portfolio

“AI is opening up the next big chapter for Veeva and life sciences. Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly. By bringing together deep industry applications, agents, data, and consulting, we are helping the industry drive new efficiencies from clinical to commercial and deliver better outcomes for patients.”

Veeva Systems CEO, on the earnings call

Forward Guidance & Outlook

For Q3 FY2027 (ending October 31, 2026), Veeva guided total revenues of $932–$935 million, non-GAAP operating income of $417–$420 million, and non-GAAP diluted EPS of $2.33–$2.34. For the full fiscal year ending January 31, 2027, guidance was raised across the board: total revenues of $3,682–$3,687 million, non-GAAP operating income of approximately $1,640 million, and non-GAAP diluted EPS of approximately $9.21. CFO Brian Van Wagener noted that second quarter results exceeded guidance on all metrics and the full-year view improved across the board.

VEEV YoY Financials

Q2 2027 vs Q2 2026 · SEC filings Q2 2026 Q2 2027
$0$300.0M$600.0M$900.0M$789.1M$928.0MRevenue$593.8M$696.0MGross Profit$195.9M$275.0MOperating Income$200.3M$273.4MNet Income
$0$300.0M$600.0M$900.0MRevenueGross ProfitOperating IncomeNet Income

VEEV Revenue by Segment

Subscription Services$766.8M+16.3%
Veeva R&D Solutions - Subscription$419.4M+19.2%
Veeva Commercial Solutions - Subscription$347.4M+13.0%
Professional Services and Other$161.2M+24.1%
Veeva R&D Solutions - Professional Services$101.5M+23.4%
Veeva Commercial Solutions - Professional Services$59.7M+25.2%

Figures from SEC filings and company reports. Not investment advice.